FDA approves Amarin’s Vascepa to reduce CV risk in narrower population

FDA approved Amarin’s Vascepa for cardiovascular risk reduction Friday, though the label is slightly more restrictive than what the company had been aiming for.

Shares of Amarin Corp. plc (NASDAQ:AMRN) gained $2.54 (11%) to $26.66 in after-hours trading...